Jun 2026 (Q2 FY26) — Jul 30, 2026
Stryker Q2 FY26 — Strong Organic Growth and Production Recovery
Read the full callStryker (SYK) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Stryker earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 6,589 | +9.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 25.2 | +6.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1,276 | +44.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
12 of 17 judged targets kept · 19 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Close of the Amplitude Vascular Systems acquisition | close in the second quarter of 2026 | Mar 2026 | We remain confident in the long-term outlook for peripheral vascular, including the ADS acquisition, which closed in the quarter | Achieved |
| Full-year adjusted earnings per share | $14.90 to $15.10 | Dec 2025 | adjusted net earnings per share to be in the range of $14.95 to $15.10 | On Track |
| Full-year adjusted effective tax rate | 15% to 16% | Dec 2025 | For 2026, we continue to expect our full year effective tax rate to be in the range of 15% to 16% | On Track |
5 of STRYKER CORP's 36 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 33 more targets are in the full ledger.
Claimed
- Delivered strong organic sales growth of 9%, with high single-digit growth from both MedSurg and Neurotechnology and Orthopedics businesses.
- Achieved adjusted EPS growth of 17.9% to $3.69, reflecting improved gross margins and rigorous operational execution.
- Recorded the best-ever Q2 for Mako installations in the U.S. and internationally, with utilization rates trending upward.
- Exited the quarter with an elevated backlog and strong orders for capital products, indicating continued demand.
- Plans to resume share repurchases in Q3 FY26, with $1 billion authorized, supported by strong cash flow generation.
Qualified
- Experienced supply disruptions in the Peripheral Vascular business, leading to a 6.7% decline in U.S. organic sales and a meaningful backorder situation.
- Full-year EPS guidance is being offset by costs from the Q1 cybersecurity event, including lost absorption from manufacturing and ongoing IT remediation expenses.
- Noted a slight slowdown in procedure volumes in Europe, though the U.S. procedural environment remains stable.
Price
$297.94 +1.11% · +$3.28
Performance −20.4% 1Y
1Y: $374.42 on 17 Oct 2025 → $297.94. High $388.35 (22 Oct 2025), low $269.75 (24 Sept 2026).
- Previous close
- $294.66
- 52-week range
- $269.75 – $388.35
- One year
- −21.85%
Overview
- Symbol
- SYK
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
12 of 17 judged targets kept · 19 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Close of the Amplitude Vascular Systems acquisition | close in the second quarter of 2026 | Mar 2026 | We remain confident in the long-term outlook for peripheral vascular, including the ADS acquisition, which closed in the quarter | Achieved |
| Full-year adjusted earnings per share | $14.90 to $15.10 | Dec 2025 | adjusted net earnings per share to be in the range of $14.95 to $15.10 | On Track |
| Full-year adjusted effective tax rate | 15% to 16% | Dec 2025 | For 2026, we continue to expect our full year effective tax rate to be in the range of 15% to 16% | On Track |
Claimed
- Delivered strong organic sales growth of 9%, with high single-digit growth from both MedSurg and Neurotechnology and Orthopedics businesses.
- Achieved adjusted EPS growth of 17.9% to $3.69, reflecting improved gross margins and rigorous operational execution.
- Recorded the best-ever Q2 for Mako installations in the U.S. and internationally, with utilization rates trending upward.
- Exited the quarter with an elevated backlog and strong orders for capital products, indicating continued demand.
- Plans to resume share repurchases in Q3 FY26, with $1 billion authorized, supported by strong cash flow generation.
Qualified
- Experienced supply disruptions in the Peripheral Vascular business, leading to a 6.7% decline in U.S. organic sales and a meaningful backorder situation.
- Full-year EPS guidance is being offset by costs from the Q1 cybersecurity event, including lost absorption from manufacturing and ongoing IT remediation expenses.
- Noted a slight slowdown in procedure volumes in Europe, though the U.S. procedural environment remains stable.
The full ledger
Open STRYKER CORP’s full ledger
A free account opens 5 company ledgers a month. All 36 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — Apr 30, 2026
Stryker Q1 FY26 — Cyber Incident Impacts Q1, Full-Year Guidance Reaffirmed
Read the full callDec 2025 (Q4 FY25) — Jan 29, 2026
Stryker Q4 FY25 — Strong Organic Growth and Mako Momentum
Read the full callEvery analysed call
Stryker earnings calls (SYK)
Financials
What the filings say
Net profit, year on year: +44% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5,494 | 6,436 | 5,866 | 6,022 | 6,057 | 7,171 | 6,020 | 6,589 |
| Operating profit | 1,085 | 581 | 837 | 1,113 | 1,135 | 1,804 | 936 | 1,659 |
| Operating margin | 19.8% | 9.0% | 14.3% | 18.5% | 18.7% | 25.2% | 15.6% | 25.2% |
| Other income | -42 | -53 | 64 | 62 | -106 | 508 | 62 | 46 |
| Interest | — | — | 137 | 159 | — | — | 148 | 141 |
| Profit before tax | 1,043 | 528 | 764 | 1,016 | 1,029 | 1,705 | 850 | 1,564 |
| Tax rate | 20.0% | −3.4% | 14.4% | 13.0% | 16.5% | 50.2% | 12.3% | 18.4% |
| Net profit | 834 | 546 | 654 | 884 | 859 | 849 | 745 | 1,276 |
| EPS ($ per share) | 2.18 | 1.43 | 1.71 | 2.32 | 2.25 | 2.21 | 1.95 | 3.32 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | 10,765 | 11,748 | 12,462 | 13,480 | 14,765 | 16,771 | 18,528 | 20,472 |
| Total liabilities | 15,499 | 17,360 | 21,246 | 19,754 | 20,268 | 21,319 | 22,337 | 25,424 |
| Fixed assets | 2,291 | 2,567 | 2,752 | 2,833 | 2,970 | 3,215 | 3,448 | 3,876 |
| Total assets | 27,229 | 30,167 | 34,330 | 34,631 | 36,884 | 39,912 | 42,971 | 47,844 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2,610 | 2,191 | 3,277 | 3,263 | 2,624 | 3,711 | 4,242 | 5,044 |
| Cash from investing | -2,857 | -1,455 | -4,701 | -859 | -2,924 | -962 | -3,000 | -4,866 |
| Cash from financing | 1,329 | 3 | -11 | -2,365 | -749 | -1,594 | -525 | 113 |
| Net cash flow | 1,074 | 721 | -1,394 | 1 | -1,100 | 1,127 | 681 | 359 |
| Capital expenditure | -572 | -649 | -487 | -525 | -588 | -575 | -755 | -761 |
| Free cash flow | 2,038 | 1,542 | 2,790 | 2,738 | 2,036 | 3,136 | 3,487 | 4,283 |
SYK revenue by segment
Med Surg and Neurotechnology shrank from 59% to 55% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Med Surg and Neurotechnology | 59% | 65% | 60% | 63% | 63% | 64% | 53% | 55% | -3.9% |
| Orthopaedics | — | — | 40% | 37% | 37% | 36% | 47% | 45% | +31.7% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 75%
- Non Us 25%
As SYK cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
137 filings between Nov 1, 2025 and Sep 24, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$586.13M
71 sales by 8 insiders
8% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 19
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
- 22
- Tax withheld — shares kept back by the company to cover tax
Also filed: 7 gifts, 4 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| STRYKER RONDA E | — | $580.89M | Aug 19, 2026 |
| Fink M Kathryn | — | $2.47M | May 11, 2026 |
| Fletcher Robert S | — | $1.39M | May 28, 2026 |
| Berry William E Jr | — | $713.8K | Nov 14, 2025 |
| King Debra | — | $277.8K | Aug 18, 2026 |
| Pierce James Andrew | — | $175.2K | Feb 2, 2026 |
| Crotty Dylan Bram | — | $144.9K | Aug 21, 2026 |
| Wells Preston Wendell | — | $60.4K | Nov 20, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Wells Preston Wendell VP, Chief Financial Officer | Other | 109 | $0 |
| Sep 22, 2026 | Wells Preston Wendell VP, Chief Financial Officer | Other | 962 | $0 |
| Aug 21, 2026 | Crotty Dylan Bram Group President | Sale | 441 | $144.9K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 3,274 | $1.12M |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 200 | $66.8K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 16,612 | $5.66M |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 805 | $276.5K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 320 | $107.8K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 40 | $13.3K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 440 | $146.6K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 10,812 | $3.67M |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 80 | $26.8K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 11,257 | $3.81M |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 2,308 | $780.1K |
| Aug 19, 2026 | STRYKER RONDA E Director | Sale | 3,852 | $1.32M |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 109,425 | $36.81M |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 131,752 | $44.22M |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 2,920 | $971.5K |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 8,404 | $2.81M |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 2,239 | $742.8K |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 3,481 | $1.18M |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 25,536 | $8.55M |
| Aug 18, 2026 | STRYKER RONDA E Director | Sale | 16,243 | $5.48M |
| Aug 18, 2026 | King Debra See Remarks | Sale | 826 | $277.8K |
| Aug 1, 2026 | Fink M Kathryn VP, Chief HR Officer | Tax withheld | 111 | $36.2K |
| Aug 1, 2026 | Montagnino Kimberly Ann VP, Chief Comm. Officer | Tax withheld | 155 | $50.5K |
| Aug 1, 2026 | King Debra See Remarks | Tax withheld | 533 | $173.6K |
| Aug 1, 2026 | Fletcher Robert S VP, Chief Legal Officer | Tax withheld | 94 | $30.6K |
| Jul 17, 2026 | Wells Preston Wendell VP, Chief Financial Officer | Other | 1,777 | $0 |
| Jun 1, 2026 | Stiles Spencer S President and COO | Gift | 1,607 | $0 |
| May 28, 2026 | Fletcher Robert S VP, Chief Legal Officer | Sale 10b5-1 plan | 1,067 | $327.9K |
| May 28, 2026 | Fletcher Robert S VP, Chief Legal Officer | Sale 10b5-1 plan | 2,809 | $861.1K |
| May 28, 2026 | Fletcher Robert S VP, Chief Legal Officer | Sale 10b5-1 plan | 165 | $50.4K |
| May 28, 2026 | Fletcher Robert S VP, Chief Legal Officer | Sale 10b5-1 plan | 120 | $36.5K |
| May 28, 2026 | Fletcher Robert S VP, Chief Legal Officer | Sale 10b5-1 plan | 125 | $38.8K |
| May 28, 2026 | Fletcher Robert S VP, Chief Legal Officer | Sale 10b5-1 plan | 258 | $79.7K |
| May 26, 2026 | STRYKER RONDA E Director | Sale | 115,960 | $36.13M |
| May 26, 2026 | STRYKER RONDA E Director | Sale | 21,807 | $6.78M |
| May 26, 2026 | STRYKER RONDA E Director | Sale | 3,707 | $1.17M |
| May 26, 2026 | STRYKER RONDA E Director | Sale | 10,407 | $3.27M |
| May 26, 2026 | STRYKER RONDA E Director | Sale | 44,060 | $13.81M |
| May 26, 2026 | STRYKER RONDA E Director | Sale | 114,059 | $35.64M |
| May 11, 2026 | Fink M Kathryn VP, Chief HR Officer | Sale | 3,500 | $992.1K |
| May 11, 2026 | Fink M Kathryn VP, Chief HR Officer | Sale | 5,220 | $1.48M |
| May 8, 2026 | Fink M Kathryn VP, Chief HR Officer | Tax withheld | 16,362 | $4.81M |
| May 8, 2026 | Fink M Kathryn VP, Chief HR Officer | Option exercise | 11,850 | $2.13M |
| May 8, 2026 | Fink M Kathryn VP, Chief HR Officer | Option exercise | 9,732 | $1.50M |
| May 6, 2026 | Suri Rajeev Director | Award | 762 | $0 |
| May 6, 2026 | Caforio Giovanni Director | Award | 762 | $0 |
| May 6, 2026 | Silvernail Andrew K Director | Award | 762 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for STRYKER CORP
Free account. Everything above stays public.
Write why you follow STRYKER CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other companies in Health Care
Nearest to Stryker by market cap among the sector's top 20 companies at Q2 2026.